These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17687682)

  • 1. Polymorphic cytochrome P450 enzymes and post-marketing drug dosage revisions: clinical relevance to dermatologic therapies.
    Saggar S; Maibach HI
    Cutan Ocul Toxicol; 2007; 26(3):171-80. PubMed ID: 17687682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
    Ingelman-Sundberg M; Sim SC; Gomez A; Rodriguez-Antona C
    Pharmacol Ther; 2007 Dec; 116(3):496-526. PubMed ID: 18001838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents.
    Murray M
    J Pharm Pharmacol; 2006 Jul; 58(7):871-85. PubMed ID: 16805946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of cytochrome P450 enzymes in the metabolism of antineoplastic drugs].
    Quiñones S L; Rosero P M; Roco A A; Moreno T I; Sasso A J; Varela F N; Cáceres L D; Saavedra S I
    Rev Med Chil; 2008 Oct; 136(10):1327-35. PubMed ID: 19194632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system.
    Sikka R; Magauran B; Ulrich A; Shannon M
    Acad Emerg Med; 2005 Dec; 12(12):1227-35. PubMed ID: 16282513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP450 pharmacogenetics for personalizing cancer therapy.
    van Schaik RH
    Drug Resist Updat; 2008 Jun; 11(3):77-98. PubMed ID: 18486526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms.
    Wijnen PA; Op den Buijsch RA; Drent M; Kuijpers PM; Neef C; Bast A; Bekers O; Koek GH
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():211-9. PubMed ID: 18081664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 enzymes and the heart.
    Chaudhary KR; Batchu SN; Seubert JM
    IUBMB Life; 2009 Oct; 61(10):954-60. PubMed ID: 19787709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene-based drug prescribing: clinical implications of the cytochrome P450 genes.
    Musana AK; Wilke RA
    WMJ; 2005 Aug; 104(6):61-6. PubMed ID: 16218319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450s in the development of target-based anticancer drugs.
    Purnapatre K; Khattar SK; Saini KS
    Cancer Lett; 2008 Jan; 259(1):1-15. PubMed ID: 18053638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 pharmacogenetics and cancer.
    Rodriguez-Antona C; Ingelman-Sundberg M
    Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the genetic causes of inter-patient variability. Clinical relevance with focus on cardiovascular drugs.
    Ginghină C; Stănescu R; Coman IM; Bărbari L; Popescu BA
    Rom J Intern Med; 2007; 45(4):313-9. PubMed ID: 18767405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cytochromes P450: xenobiotic metabolism, regulation and clinical importance].
    Guéguen Y; Mouzat K; Ferrari L; Tissandie E; Lobaccaro JM; Batt AM; Paquet F; Voisin P; Aigueperse J; Gourmelon P; Souidi M
    Ann Biol Clin (Paris); 2006; 64(6):535-48. PubMed ID: 17162257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalized proteochemometric model of multiple cytochrome p450 enzymes and their inhibitors.
    Kontijevskis A; Komorowski J; Wikberg JE
    J Chem Inf Model; 2008 Sep; 48(9):1840-50. PubMed ID: 18693719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
    Duricová J; Grundmann M
    Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer pharmacogenomics: achievements in basic research.
    Nakajima M; Yokoi T
    Int J Clin Oncol; 2005 Feb; 10(1):14-9. PubMed ID: 15729595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.
    Ma JD; Nafziger AN; Bertino JS
    J Clin Pharmacol; 2004 May; 44(5):447-56. PubMed ID: 15102864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.